Research ExplorerPublicationsEstimating Long-Term Survival Outcomes for Tumor-Agnostic Th...

Estimating Long-Term Survival Outcomes for Tumor-Agnostic Therapies: Larotrectinib Case Study

Standard

Estimating Long-Term Survival Outcomes for Tumor-Agnostic Therapies: Larotrectinib Case Study. / Briggs, Andrew; Paracha, Noman; Rosettie, Katherine; Upton, Alexander; Bokemeyer, Carsten; Lassen, Ulrik; Sullivan, Sean D.

In: ONCOLOGY-BASEL, Vol. 100, No. 2, 2022, p. 124-130.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Briggs, A, Paracha, N, Rosettie, K, Upton, A, Bokemeyer, C, Lassen, U & Sullivan, SD 2022, 'Estimating Long-Term Survival Outcomes for Tumor-Agnostic Therapies: Larotrectinib Case Study', ONCOLOGY-BASEL, vol. 100, no. 2, pp. 124-130. https://doi.org/10.1159/000519767

APA

Briggs, A., Paracha, N., Rosettie, K., Upton, A., Bokemeyer, C., Lassen, U., & Sullivan, S. D. (2022). Estimating Long-Term Survival Outcomes for Tumor-Agnostic Therapies: Larotrectinib Case Study. ONCOLOGY-BASEL, 100(2), 124-130. https://doi.org/10.1159/000519767

Vancouver

Briggs A, Paracha N, Rosettie K, Upton A, Bokemeyer C, Lassen U et al. Estimating Long-Term Survival Outcomes for Tumor-Agnostic Therapies: Larotrectinib Case Study. ONCOLOGY-BASEL. 2022;100(2):124-130. https://doi.org/10.1159/000519767

Bibtex

@article{776d9186a42e4c2cb62a316afe09a43a,
title = "Estimating Long-Term Survival Outcomes for Tumor-Agnostic Therapies: Larotrectinib Case Study",
abstract = "BACKGROUND: Larotrectinib is a precision oncology treatment for solid tumors with neurotrophic tyrosine receptor kinase (NTRK) gene fusions. Larotrectinib efficacy has been evaluated in single-arm basket trials with limited follow-up and sample sizes at the initial regulatory approval due to the rarity of solid tumors with NTRK gene fusion.OBJECTIVES: We aim to demonstrate that trends in progression-free survival (PFS) and overall survival (OS) in survival data with longer follow-up may be predicted from long-term survival estimates from survival data with shorter follow-up, including predictions for median survival when it is not observed in the trial.METHODS: Patient-level data were pooled from 3 clinical trials (NCT02122913, NCT02576431, and NCT02637687) using the 2018 and 2020 data cuts for the same subset of pediatric and adult patients. The Weibull distribution was selected for survival models. Survival predictions using 2018 data were compared to 2020 Kaplan-Meier (KM) curves.RESULTS: A total of 102 patients representing 15 tumor types were included in the analysis, with a mean age of 37 years. When comparing PFS from the 2018 survival prediction to observed 2020 KM data, the 12-month PFS rate was identical (66.6%). The 36-month PFS rate was lower for the 2018 prediction (35.3%) compared to 2020 KM data (44.4%). The median OS had not yet been reached in either data cut but was predicted to be 90 months using the 2018 data. When comparing OS from the 2018 survival prediction to the observed 2020 KM data, the 12-month OS rate was 89.0% and 86.6% and the 48-month OS rate was 67.2% and 63.0%, respectively.CONCLUSION: Long-term PFS predictions deviated from observed PFS rates due to response differences across tumor types and heavy censoring towards the end of the survival curve. However, for OS, the 48-month survival prediction was consistent with the observed 2020 KM estimate.",
author = "Andrew Briggs and Noman Paracha and Katherine Rosettie and Alexander Upton and Carsten Bokemeyer and Ulrik Lassen and Sullivan, {Sean D}",
note = "{\textcopyright} 2021 The Author(s). Published by S. Karger AG, Basel.",
year = "2022",
doi = "10.1159/000519767",
language = "English",
volume = "100",
pages = "124--130",
journal = "ONCOLOGY-BASEL",
issn = "0030-2414",
publisher = "S. Karger AG",
number = "2",

}

RIS

TY - JOUR

T1 - Estimating Long-Term Survival Outcomes for Tumor-Agnostic Therapies: Larotrectinib Case Study

AU - Briggs, Andrew

AU - Paracha, Noman

AU - Rosettie, Katherine

AU - Upton, Alexander

AU - Bokemeyer, Carsten

AU - Lassen, Ulrik

AU - Sullivan, Sean D

N1 - © 2021 The Author(s). Published by S. Karger AG, Basel.

PY - 2022

Y1 - 2022

N2 - BACKGROUND: Larotrectinib is a precision oncology treatment for solid tumors with neurotrophic tyrosine receptor kinase (NTRK) gene fusions. Larotrectinib efficacy has been evaluated in single-arm basket trials with limited follow-up and sample sizes at the initial regulatory approval due to the rarity of solid tumors with NTRK gene fusion.OBJECTIVES: We aim to demonstrate that trends in progression-free survival (PFS) and overall survival (OS) in survival data with longer follow-up may be predicted from long-term survival estimates from survival data with shorter follow-up, including predictions for median survival when it is not observed in the trial.METHODS: Patient-level data were pooled from 3 clinical trials (NCT02122913, NCT02576431, and NCT02637687) using the 2018 and 2020 data cuts for the same subset of pediatric and adult patients. The Weibull distribution was selected for survival models. Survival predictions using 2018 data were compared to 2020 Kaplan-Meier (KM) curves.RESULTS: A total of 102 patients representing 15 tumor types were included in the analysis, with a mean age of 37 years. When comparing PFS from the 2018 survival prediction to observed 2020 KM data, the 12-month PFS rate was identical (66.6%). The 36-month PFS rate was lower for the 2018 prediction (35.3%) compared to 2020 KM data (44.4%). The median OS had not yet been reached in either data cut but was predicted to be 90 months using the 2018 data. When comparing OS from the 2018 survival prediction to the observed 2020 KM data, the 12-month OS rate was 89.0% and 86.6% and the 48-month OS rate was 67.2% and 63.0%, respectively.CONCLUSION: Long-term PFS predictions deviated from observed PFS rates due to response differences across tumor types and heavy censoring towards the end of the survival curve. However, for OS, the 48-month survival prediction was consistent with the observed 2020 KM estimate.

AB - BACKGROUND: Larotrectinib is a precision oncology treatment for solid tumors with neurotrophic tyrosine receptor kinase (NTRK) gene fusions. Larotrectinib efficacy has been evaluated in single-arm basket trials with limited follow-up and sample sizes at the initial regulatory approval due to the rarity of solid tumors with NTRK gene fusion.OBJECTIVES: We aim to demonstrate that trends in progression-free survival (PFS) and overall survival (OS) in survival data with longer follow-up may be predicted from long-term survival estimates from survival data with shorter follow-up, including predictions for median survival when it is not observed in the trial.METHODS: Patient-level data were pooled from 3 clinical trials (NCT02122913, NCT02576431, and NCT02637687) using the 2018 and 2020 data cuts for the same subset of pediatric and adult patients. The Weibull distribution was selected for survival models. Survival predictions using 2018 data were compared to 2020 Kaplan-Meier (KM) curves.RESULTS: A total of 102 patients representing 15 tumor types were included in the analysis, with a mean age of 37 years. When comparing PFS from the 2018 survival prediction to observed 2020 KM data, the 12-month PFS rate was identical (66.6%). The 36-month PFS rate was lower for the 2018 prediction (35.3%) compared to 2020 KM data (44.4%). The median OS had not yet been reached in either data cut but was predicted to be 90 months using the 2018 data. When comparing OS from the 2018 survival prediction to the observed 2020 KM data, the 12-month OS rate was 89.0% and 86.6% and the 48-month OS rate was 67.2% and 63.0%, respectively.CONCLUSION: Long-term PFS predictions deviated from observed PFS rates due to response differences across tumor types and heavy censoring towards the end of the survival curve. However, for OS, the 48-month survival prediction was consistent with the observed 2020 KM estimate.

U2 - 10.1159/000519767

DO - 10.1159/000519767

M3 - SCORING: Journal article

C2 - 34844255

VL - 100

SP - 124

EP - 130

JO - ONCOLOGY-BASEL

JF - ONCOLOGY-BASEL

SN - 0030-2414

IS - 2

ER -